Edgestream Partners L.P. Has $6.03 Million Stake in Merit Medical Systems, Inc. $MMSI

Posted by Brian Himes on Jul 31st, 2026

Edgestream Partners L.P. increased its stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) by 96.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 87,471 shares of the medical instruments supplier’s stock after buying an additional 42,992 shares during the quarter. Edgestream Partners L.P.’s holdings in Merit Medical Systems were worth $6,029,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MMSI. Smith Group Asset Management LLC increased its stake in Merit Medical Systems by 8.2% in the 1st quarter. Smith Group Asset Management LLC now owns 6,415 shares of the medical instruments supplier’s stock valued at $442,000 after buying an additional 485 shares during the period. Amundi lifted its position in Merit Medical Systems by 2.8% in the 1st quarter. Amundi now owns 112,099 shares of the medical instruments supplier’s stock worth $7,727,000 after buying an additional 3,027 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Merit Medical Systems by 16.2% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,551 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 216 shares during the period. Talon Private Wealth LLC acquired a new stake in shares of Merit Medical Systems during the 1st quarter valued at $593,000. Finally, California State Teachers Retirement System grew its holdings in shares of Merit Medical Systems by 23.1% during the 1st quarter. California State Teachers Retirement System now owns 69,505 shares of the medical instruments supplier’s stock valued at $4,791,000 after acquiring an additional 13,039 shares in the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MMSI. Weiss Ratings lowered Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Robert W. Baird set a $83.00 target price on Merit Medical Systems in a research note on Friday, May 1st. Wells Fargo & Company cut their price target on Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Barrington Research reduced their price target on Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating for the company in a report on Monday, April 20th. Finally, JPMorgan Chase & Co. lowered their price target on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.78.

Get Our Latest Research Report on Merit Medical Systems

Insider Activity

In other Merit Medical Systems news, insider Brian G. Lloyd purchased 2,000 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were bought at an average cost of $62.62 per share, with a total value of $125,240.00. Following the transaction, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. This represents a 39.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.70% of the stock is currently owned by insiders.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

Positive Sentiment: Q2 earnings and revenue beat estimates. Merit reported non-GAAP EPS of $1.19, up from $1.01 a year earlier and well above the $0.96 consensus estimate. Revenue rose 9.5% year over year to $418.8 million, exceeding expectations of $405.3 million. Merit Medical Surpasses Q2 Earnings and Revenue Estimates
Positive Sentiment: Profitability improved. GAAP operating margin expanded to 14.4% from 12.3%, while non-GAAP operating margin increased to 22.6% from 21.2%. GAAP EPS rose 20%, and non-GAAP EPS increased 18% year over year. Merit Medical Reports Second Quarter 2026 Results
Positive Sentiment: Full-year EPS guidance was raised or reaffirmed above consensus. Merit provided 2026 adjusted EPS guidance of $4.25 to $4.35, compared with the analyst consensus of $3.98. Revenue guidance of approximately $1.6 billion was in line with expectations, indicating that earnings growth and margin execution are key drivers of the outlook. Merit Medical Raises 2026 Outlook
Neutral Sentiment: The earnings call transcript and additional metric analysis may provide more detail on product demand, regional performance, and management’s expectations, but the headline release did not indicate a material change to the revenue outlook. MMSI Q2 2026 Earnings Call Transcript
Negative Sentiment: Cash generation weakened year to date. Operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million. Investors may monitor whether this reflects temporary working-capital needs or a more persistent pressure on cash conversion. Merit Medical Q2 Financial Highlights

Merit Medical Systems Stock Performance

NASDAQ:MMSI opened at $83.35 on Friday. The firm has a market capitalization of $4.97 billion, a PE ratio of 36.08, a PEG ratio of 2.51 and a beta of 0.52. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $94.75. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $69.45 and its 200 day simple moving average is $71.69.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, sell-side analysts anticipate that Merit Medical Systems, Inc. will post 3.62 EPS for the current year.

Merit Medical Systems Company Profile

(Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.